Navidea Biopharmaceuticals Initiates Pivotal Phase 3 Registration Program of NAV5001 SPECT Imaging Agent for Parkinson’s Disease
- Phase 3 Studies to Evaluate the Use of NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the first subject has been enrolled in one of the two planned NAV5001, pivotal Phase 3 clinical trials. The trial will assess the safety and efficacy of NAV5001, an investigational imaging agent as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor. NAV5001 is an investigational imaging agent used to visualize dopamine transporter protein (DAT) located on the nigrostriatal neurons in the brain using single photon emission tomography (SPECT) imaging. Loss of these neurons is a widely recognized hallmark of Parkinson’s disease and other forms of Parkinsonism.
“Reducing diagnostic uncertainty and error rates for patients with movement disorders who often exhibit similar clinical symptoms would afford great value, especially early in the initial clinical presentation, and may lead to improved clinical decision-making and patient management,” said Ira Goodman, MD, Principle Investigator, Compass Research, LLC, Orlando, FL. “We look forward to evaluating the attributes of NAV5001 as, unlike other agents, its rapid kinetics indicate that we can scan patients very quickly following injection. This is beneficial both for elderly patients and other patients displaying movement symptoms, as well as providing an avenue toward enhanced efficiency, productivity and patient management in the clinic.”
“We are excited to begin this pivotal Phase 3 trial for NAV5001. We believe that NAV5001 has the potential to play an important role in clinical practice where physicians often struggle with the differential diagnosis of movement disorders and tremors such as are present in Parkinson’s disease,” said Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “This registration program will focus on patients with emerging symptoms in whom diagnostic uncertainty and unmet need are highest. Results from earlier trials using NAV5001 suggest that it may be an effective, well-tolerated imaging agent. The high affinity for DAT with resulting clear images can assist physicians in reaching an accurate diagnosis sooner, and the rapid kinetics with minimal time between injection and scanning and time in the SPECT scanner not only decrease patient exposure and but also facilitate increased efficiency with potential cost savings for the nuclear medicine facility.”
About the NAV5001 Phase 3 Clinical Program
The open-label,
pivotal NAV5001 Phase 3 program consists of two similar clinical trials
that will run in parallel and enroll approximately 550 total subjects
who exhibit early stage tremor. Each Phase 3 trial was the subject of a
special protocol assessment (SPA) agreement with FDA. The primary
endpoint of both studies is to evaluate the relative diagnostic efficacy
of the NAV5001 SPECT images compared with the diagnosis made by
neurologists and that established by a consensus panel of three movement
disorder specialists as the ‘Standard of Truth’. In one study, each
subject will undergo SPECT imaging with NAV5001 only. In the second
study, subjects will undergo SPECT imaging with both NAV5001 and an
alternative SPECT agent, ioflupane, in a cross-over comparison design.
To learn more, see this study listing on ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/show/NCT01950455?term=NAV5001&rank=1
About NAV5001
Iodine-123 labeled NAV5001 is a patented,
novel, small molecule radiopharmaceutical used with single photon
emission computed tomography (SPECT) imaging to identify the status of
specific regions in the brains of patients suspected of having
Parkinson’s disease. The agent binds to the dopamine transporter (DAT)
on the cell surface of dopaminergic neurons in the striatum and
substantia nigra regions of the brain. Loss of these neurons is a widely
recognized hallmark of Parkinson’s disease and other forms of
Parkinsonism.
NAV5001 has been administered to more than 600 subjects in multi-phase clinical trials to date. Results from these clinical trials have demonstrated that NAV5001 has high affinity for DAT and rapid kinetics which enable the generation of clean diagnostic images quickly, beginning within approximately 20 minutes after injection. In addition to its potential use as an aid in the differential diagnosis of Parkinsonian syndromes and movement disorders, NAV5001 may also be useful in the diagnosis of Dementia with Lewy Bodies (DLB), which is the second most common cause of progressive dementia after Alzheimer's disease.
About Parkinsonian Syndromes, Parkinson’s Disease and other movement
disorders
Parkinsonian syndromes and movement disorders such as
Essential Tremor represent a class of neurodegenerative diseases with
important diagnostic needs. Parkinsonian syndromes (PS) are
neurodegenerative disorders that affect a person’s ability to control
movement and other muscle functions. Parkinson's Disease is the
most common form of Parkinsonian Syndromes believed to be caused by loss
of dopamine producing neurons in the brain and with first symptoms such
as tremor, rigidity, or slow movement. Other less common Parkinsonian
Syndromes include multiple system atrophy (MSA), Progressive
Supranuclear Palsy (PSP), and drug-induced Parkinsonism. The Parkinson’s
Disease Foundation (PDF) estimates that up to 10 million people
worldwide are living with PD, including 1 million people in the U.S.
Approximately 60,000 new cases of PD are diagnosed in the U.S. each year.1
The International Essential Tremor Foundation estimates that as many as
10 million people in the United States are afflicted by essential tremor.
PD is commonly misdiagnosed or completely missed in clinical evaluations as symptoms are often attributed to the normal aging process. Essential tremor and the other similar conditions are also common sources of confusion in PD diagnosis. Collectively, there are over 25 million people in the U.S. and Europe with some type of movement disorder, comprising a large differential diagnosis population.
About Compass Research, LLC
Compass Research is a
multi-therapeutic, phase 1-4 clinical research company headquartered in
Orlando, FL, with additional research centers located in Oviedo and
Leesburg, FL. With proven experience since 1992, Compass has grown in
size and industry presence to become one of the premier research sites
in the world. Compass serves over 200 sponsors, from small biotech
companies to the world’s largest pharmaceutical companies, and has
completed over 1,300 trials. With more than 300 years of combined
clinical research experience, the Compass team focuses on
neurodegenerative research and is renowned for its strength in enrolling
specialty patient populations and completing advanced diagnostic
procedures. For more information, please visit www.CompassResearch.com.
About Navidea Biopharmaceuticals, Inc.
Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing
multiple precision diagnostic products and platforms including NAV4694,
NAV5001, Manocept™ and RIGScanTM , to help identify the sites
and pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making and, ultimately, patient care.
Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea’s
first commercial product from the Manocept platform, was approved by the
FDA in March 2013. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
1 Parkinson’s Disease Foundation. Statistics on Parkinson’s: http://www.pdf.org/en/parkinson_statistics. Accessed on August 21, 2013.
Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive
VP & CFO
or
Sharon Correia, 978-655-2686
Associate
Director, Corporate Communications
Source: Navidea Biopharmaceuticals, Inc.
Released December 3, 2013